BNP Paribas Arbitrage SNC Acquires 107,288 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

BNP Paribas Arbitrage SNC increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) by 85.8% in the 3rd quarter, Holdings Channel reports. The fund owned 232,350 shares of the medical equipment provider’s stock after buying an additional 107,288 shares during the quarter. BNP Paribas Arbitrage SNC’s holdings in Lantheus were worth $16,341,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. CWM LLC increased its stake in shares of Lantheus by 82.1% in the 3rd quarter. CWM LLC now owns 366 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 165 shares in the last quarter. Veriti Management LLC increased its stake in Lantheus by 5.4% during the 3rd quarter. Veriti Management LLC now owns 3,270 shares of the medical equipment provider’s stock valued at $230,000 after purchasing an additional 168 shares in the last quarter. C M Bidwell & Associates Ltd. increased its stake in Lantheus by 9.0% during the 3rd quarter. C M Bidwell & Associates Ltd. now owns 2,970 shares of the medical equipment provider’s stock valued at $209,000 after purchasing an additional 245 shares in the last quarter. Arizona State Retirement System increased its stake in Lantheus by 1.6% during the 3rd quarter. Arizona State Retirement System now owns 18,651 shares of the medical equipment provider’s stock valued at $1,312,000 after purchasing an additional 290 shares in the last quarter. Finally, Strs Ohio increased its stake in Lantheus by 1.4% during the 3rd quarter. Strs Ohio now owns 22,500 shares of the medical equipment provider’s stock valued at $1,582,000 after purchasing an additional 300 shares in the last quarter. 97.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Lantheus news, insider Etienne Montagut sold 14,179 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $72.56, for a total transaction of $1,028,828.24. Following the sale, the insider now owns 90,825 shares in the company, valued at approximately $6,590,262. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Lantheus news, CFO Robert J. Jr. Marshall sold 20,587 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $72.56, for a total transaction of $1,493,792.72. Following the sale, the chief financial officer now owns 138,152 shares in the company, valued at approximately $10,024,309.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Etienne Montagut sold 14,179 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $72.56, for a total transaction of $1,028,828.24. Following the sale, the insider now owns 90,825 shares in the company, valued at approximately $6,590,262. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 152,801 shares of company stock valued at $11,138,348. 1.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on LNTH shares. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, February 27th. Mizuho raised their price target on shares of Lantheus from $105.00 to $115.00 and gave the company a “buy” rating in a report on Friday, February 24th. SVB Leerink started coverage on shares of Lantheus in a report on Wednesday, November 30th. They set an “outperform” rating on the stock. Finally, JMP Securities started coverage on shares of Lantheus in a report on Wednesday, March 8th. They set an “outperform” rating and a $120.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $107.33.

Lantheus Stock Performance

LNTH opened at $73.02 on Wednesday. The company has a current ratio of 2.74, a quick ratio of 2.59 and a debt-to-equity ratio of 1.25. The company has a market cap of $4.93 billion, a price-to-earnings ratio of 214.76 and a beta of 0.64. The company’s 50 day moving average is $60.48 and its 200 day moving average is $63.76. Lantheus Holdings, Inc. has a 12-month low of $47.46 and a 12-month high of $87.47.

Lantheus (NASDAQ:LNTHGet Rating) last posted its quarterly earnings data on Thursday, February 23rd. The medical equipment provider reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $0.41. The company had revenue of $263.17 million for the quarter, compared to the consensus estimate of $244.61 million. Lantheus had a net margin of 3.00% and a return on equity of 51.60%. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 4.46 EPS for the current year.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.

Read More

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.